This patent, which is scheduled to expire in 2040, stems from a patent application filed in March 2020 by Massachusetts General Hospital (MGH). Theratechnologies has an exclusive license with MGH to this patent.
The company submitted a phase 3 study protocol to the U.S. FDA in early September 2020, with the aim of beginning clinical trial in 1Q-2021.
Theratechnologies intends to use a new investigational formulation of tesamorelin, known as “F8”, for the conduct of such Phase 3 clinical trial. The Company is also working on the development of a convenient, multi-dose pen injector using the F8 formulation.